Pioneer of prostate cancer: past, present and the future of <i>FOXA1</i>

doi:10.1007/s13238-020-00786-8

Protein Cell

2021, Vol. 12

Issue (1) : 29-38 https://doi.org/10.1007/s13238-020-00786-8

REVIEW

Pioneer of prostate cancer: past, present and the future of FOXA1

Mona Teng^1,², Stanley Zhou^1,², Changmeng Cai³, Mathieu Lupien^1,^2,⁴(

), Housheng Hansen He^1,²(

)

¹. Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
². Department of Medical Biophysics, University of Toronto, Toronto, Canada
³. Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA 02125, USA
⁴. 4Ontario Institute for Cancer Research, Toronto, ON, Canada

Download: PDF(474 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Prostate cancer is the most commonly diagnosed noncutaneous cancers in North American men. While androgen deprivation has remained as the cornerstone of prostate cancer treatment, resistance ensues leading to lethal disease. Forkhead box A1 (FOXA1) encodes a pioneer factor that induces open chromatin conformation to allow the binding of other transcription factors. Through direct interactions with the Androgen Receptor (AR), FOXA1 helps to shape AR signaling that drives the growth and survival of normal prostate and prostate cancer cells. FOXA1 also possesses an AR-independent role of regulating epithelial-to-mesenchymal transition (EMT). In prostate cancer, mutations converge onto the coding sequence and cis-regulatory elements (CREs) of FOXA1, leading to functional alterations. In addition, FOXA1 activity in prostate cancer can be modulated post-translationally through various mechanisms such as LSD1-mediated protein demethylation. In this review, we describe the latest discoveries related to the function and regulation of FOXA1 in prostate cancer, pointing to their relevance to guide future clinical interventions.

Keywords FOXA1 pioneer factor transcription factor prostate cancer epigenetics

Corresponding Author(s): Mathieu Lupien,Housheng Hansen He

Online First Date: 21 October 2020 Issue Date: 11 February 2021

Cite this article:

Mona Teng,Stanley Zhou,Changmeng Cai, et al. Pioneer of prostate cancer: past, present and the future of FOXA1[J]. Protein Cell, 2021, 12(1): 29-38.

URL:

https://academic.hep.com.cn/pac/EN/10.1007/s13238-020-00786-8
https://academic.hep.com.cn/pac/EN/Y2021/V12/I1/29

1	EJ Adams, WR Karthaus, E Hoover, D Liu, A Gruet, Z Zhang, H Cho, R DiLoreto, S Chhangawala, Y Liuet al. (2019) FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature 571:408–412 https://doi.org/10.1038/s41586-019-1318-9
2	M Ahmed, RC Sallari, H Guo, JH Moore, HH He, M Lupien (2017) Variant Set Enrichment: an R package to identify diseaseassociated functional genomic regions. BioData Min 10:9 https://doi.org/10.1186/s13040-017-0129-5
3	American Cancer Society (2019) Cancer Facts & Figures 2019
4	M Annala, S Taavitsainen, G Vandekerkhove, JVW Bacon, K Beja, KN Chi, M Nykter, AW Wyatt (2018)Frequent mutation of the FOXA1 untranslated region in prostate cancer. Commun Biol 1:122 https://doi.org/10.1038/s42003-018-0128-1
5	CH Arrowsmith, C Bountra, PV Fish, K Lee, M Schapira (2012) Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 11:384–400 https://doi.org/10.1038/nrd3674
6	CE Barbieri, SC Baca, MS Lawrence, F Demichelis, M Blattner, J-P Theurillat, TA White, P Stojanov, E Van Allen, N Stranskyet al. (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44:685–689 https://doi.org/10.1038/ng.2279
7	H Beltran, D Prandi, JM Mosquera, M Benelli, L Puca, J Cyrta, C Marotz, E Giannopoulou, BVSK Chakravarthi, S Varamballyet al. (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298–305 https://doi.org/10.1038/nm.4045
8	H Beltran, A Romanel, V Conteduca, N Casiraghi, M Sigouros, GM Franceschini, F Orlando, T Fedrizzi, S-Y Ku, E Dannet al. (2020) Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest 130:1653–1668 https://doi.org/10.1172/JCI131041
9	C Cai, HH He, S Gao, S Chen, Z Yu, Y Gao, S Chen, MW Chen, J Zhang, M Ahmedet al. (2014) Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep 9:1618–1627 https://doi.org/10.1016/j.celrep.2014.11.008
10	Canadian Cancer Society (2019) Canadian Cancer Statistics 2019 Cancer Genome Atlas Research Network (2015) The Molecular Taxonomy of Primary Prostate Cancer. Cell 163:1011–1025
11	KL Clark, ED Halay, E Lai, SK Burley (1993) Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 364:412–420 https://doi.org/10.1038/364412a0
12	CV Dang, EP Reddy, KM Shokat, L Soucek (2017) Drugging the “undruggable” cancer targets. Nat Rev Cancer 17:502–508 https://doi.org/10.1038/nrc.2017.36
13	JR Dixon, DU Gorkin, B Ren (2016) Chromatin domains: the unit of chromosome organization. Mol Cell 62:668–680 https://doi.org/10.1016/j.molcel.2016.05.018
14	JR Dixon, S Selvaraj, F Yue, A Kim, Y Li, Y Shen, M Hu, JS Liu, B Ren (2012) Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485:376–380 https://doi.org/10.1038/nature11082
15	SMG Espiritu, LY Liu, Y Rubanova, V Bhandari, EM Holgersen, LM Szyca, NS Fox, MLK Chua, TN Yamaguchi, LE Heisleret al. (2018) The evolutionary landscape of localized prostate cancers drives clinical aggression. Cell 173:1003–1013.e15 https://doi.org/10.1016/j.cell.2018.03.029
16	Y Fang, G Liao, B Yu (2019) LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol 12:129 https://doi.org/10.1186/s13045-019-0811-9
17	S Farashi, T Kryza, J Clements, J Batra (2019) Post-GWAS in prostate cancer: from genetic association to biological contribution. Nat Rev Cancer 19:46–59 https://doi.org/10.1038/s41568-018-0087-3
18	M Fraser, VY Sabelnykova, TN Yamaguchi, LE Heisler, J Livingstone, V Huang, Y-J Shiah, F Yousif, X Lin, AP Masellaet al. (2017) Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541:359–364 https://doi.org/10.1038/nature20788
19	N Gao, J Zhang, MA Rao, TC Case, J Mirosevich, Y Wang, R Jin, A Gupta, PS Rennie, RJ Matusik (2003) The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol 17:1484–1507 https://doi.org/10.1210/me.2003-0020
20	S Gao, S Chen, D Han, D Barrett, W Han, M Ahmed, S Patalano, JA Macoska, HH He, C Cai (2019) Forkhead domain mutations in FOXA1 drive prostate cancer progression. Cell Res 29:770–772 https://doi.org/10.1038/s41422-019-0203-2
21	S Gao, S Chen, D Han, Z Wang, M Li, W Han, A Besschetnova, M Liu, F Zhou, D Barrettet al. (2020) Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet. https://doi.org/10.1038/s41588-020-0681-7
22	J Gerhardt, M Montani, P Wild, M Beer, F Huber, T Hermanns, M Müntener, G Kristiansen (2012) FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol 180:848–861 https://doi.org/10.1016/j.ajpath.2011.10.021
23	CS Grasso, Y-M Wu, DR Robinson, X Cao, SM Dhanasekaran, AP Khan, MJ Quist, X Jing, RJ Lonigro, JC Brenneret al. (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239–243 https://doi.org/10.1038/nature11125
24	GD Grossfeld, DM Latini, DP Lubeck, SS Mehta, PR Carroll (2003) Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 169:157–163 https://doi.org/10.1016/S0022-5347(05)64058-X
25	B Gui, F Gui, T Takai, C Feng, X Bai, L Fazli, X Dong, S Liu, X Zhang, W Zhanget al. (2019) Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proceedings of the National Academy of Sciences 116:14573–14582 https://doi.org/10.1073/pnas.1908547116
26	W Hankey, Z Chen, Q Wang (2020) Shaping chromatin states in prostate cancer by pioneer transcription factors. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-19-3447
27	DJ Hazelett, SG Coetzee, GA Coetzee (2013) A rare variant, which destroys a FoxA1 site at 8q24, is associated with prostate cancer risk. Cell Cycle 12:379–380 https://doi.org/10.4161/cc.23201
28	FW Huang, JM Mosquera, A Garofalo, C Oh, M Baco, A Amin-Mansour, B Rabasha, S Bahl, SA Mullane, BD Robinsonet al. (2017) Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations. Cancer Discov 7:973–983 https://doi.org/10.1158/2159-8290.CD-16-0960
29	J Huang, R Sengupta, AB Espejo, MG Lee, JA Dorsey, M Richter, S Opravil, R Shiekhattar, MT Bedford, T Jenuweinet al. (2007) p53 is regulated by the lysine demethylase LSD1. Nature 449:105–108 https://doi.org/10.1038/nature06092
30	M Iwafuchi, I Cuesta, G Donahue, N Takenaka, AB Osipovich, MA Magnuson, H Roder, SH Seeholzer, P Santisteban, KS Zaret (2020) Gene network transitions in embryos depend upon interactions between a pioneer transcription factor and core histones. Nat Genet 52:418–427 https://doi.org/10.1038/s41588-020-0591-8
31	H-J Jin, JC Zhao, I Ogden, RC Bergan, J Yu (2013) Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res 73:3725–3736 https://doi.org/10.1158/0008-5472.CAN-12-3468
32	H-J Jin, JC Zhao, L Wu, J Kim, J Yu (2014) Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun 5:3972 https://doi.org/10.1038/ncomms4972
33	J Kim, H Jin, JC Zhao, YA Yang, Y Li, X Yang, X Dong, J Yu (2017) FOXA1 inhibits prostate cancer neuroendocrine differentiation. Oncogene 36:4072–4080 https://doi.org/10.1038/onc.2017.50
34	S Kohler, LA Cirillo (2010) Stable chromatin binding prevents FoxA acetylation, preserving FoxA chromatin remodeling. J Biol Chem 285:464–472 https://doi.org/10.1074/jbc.M109.063149
35	J Li, C Xu, HJ Lee, S Ren, X Zi, Z Zhang, H Wang, Y Yu, C Yang, X Gaoet al. (2020) A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature 580:93–99 https://doi.org/10.1038/s41586-020-2135-x
36	M Lupien, J Eeckhoute, CA Meyer, Q Wang, Y Zhang, W Li, JS Carroll, XS Liu, M Brown (2008) FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132:958–970 https://doi.org/10.1016/j.cell.2008.01.018
37	MT Maurano, R Humbert, E Rynes, RE Thurman, E Haugen, H Wang, AP Reynolds, R Sandstrom, H Qu, J Brodyet al. (2012) Systematic localization of common disease-associated variation in regulatory DNA. Science 337:1190–1195 https://doi.org/10.1126/science.1222794
38	P Mazrooei, KJ Kron, Y Zhu, S Zhou, G Grillo, T Mehdi, M Ahmed, TM Severson, P Guilhamon, NS Armstronget al. (2019) Cistrome partitioning reveals convergence of somatic mutations and risk variants on master transcription regulators in primary prostate tumors. Cancer Cell 36:674–689.e6 https://doi.org/10.1016/j.ccell.2019.10.005
39	E Metzger, M Wissmann, N Yin, JM Müller, R Schneider, AHFM Peters, T Günther, R Buettner, R Schüle (2005) LSD1 demethylates repressive histone marks to promote androgen-receptordependent transcription. Nature 437:436–439 https://doi.org/10.1038/nature04020
40	S Müller, S Ackloo, CH Arrowsmith, M Bauser, JL Baryza, J Blagg, J Böttcher, C Bountra, PJ Brown, ME Bunnageet al. (2018) Science forum: donated chemical probes for open science. Elife 7:e34311 https://doi.org/10.7554/eLife.34311
41	EP Nora, BR Lajoie, EG Schulz, L Giorgetti, I Okamoto, N Servant, T Piolot, NL van Berkum, J Meisig, J Sedatet al. (2012) Spatial partitioning of the regulatory landscape of the X-inactivation centre. Nature 485:381–385 https://doi.org/10.1038/nature11049
42	A Parolia, M Cieslik, S-C Chu, L Xiao, T Ouchi, Y Zhang, X Wang, P Vats, X Cao, S Pitchiayaet al. (2019) Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature 571:413–418 https://doi.org/10.1038/s41586-019-1347-4
43	MM Pomerantz, F Li, DY Takeda, R Lenci, A Chonkar, M Chabot, P Cejas, F Vazquez, J Cook, RA Shivdasaniet al. (2015) The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet 47:1346–1351 https://doi.org/10.1038/ng.3419
44	MM Pomerantz, X Qiu, Y Zhu, DY Takeda, W Pan, SC Baca, A Gusev, KD Korthauer, TM Severson, G Haet al. (2020) Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet 52:790–799 https://doi.org/10.1038/s41588-020-0664-8
45	DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, V Kothari, MD Perry, AM Baileyet al. (2018) Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174:758–769.e9
46	M Rotinen, S You, J Yang, SG Coetzee, M Reis-Sobreiro, W-C Huang, F Huang, X Pan, A Yáñez , DJ Hazelettet al. (2018) ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat Med 24:1887–1898 https://doi.org/10.1038/s41591-018-0241-1
47	R Sabarinathan, L Mularoni, J Deu-Pons, A Gonzalez-Perez, N López-Bigas (2016) Nucleotide excision repair is impaired by binding of transcription factors to DNA. Nature 532:264–267 https://doi.org/10.1038/nature17661
48	B Sahu, M Laakso, K Ovaska, T Mirtti, J Lundin, A Rannikko, A Sankila, J-P Turunen, M Lundin, J Konstiet al. (2011) Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 30:3962–3976 https://doi.org/10.1038/emboj.2011.328
49	B Sahu, M Laakso, P Pihlajamaa, K Ovaska, I Sinielnikov, S Hautaniemi, OA Jänne (2013) FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res 73:1570–1580 https://doi.org/10.1158/0008-5472.CAN-12-2350
50	S Scheer, S Ackloo, TS Medina, M Schapira, F Li, JA Ward, AM Lewis, JP Northrop, PL Richardson, HÜ Kaniskanet al. (2019) A chemical biology toolbox to study protein methyltransferases and epigenetic signaling. Nat Commun 10:19 https://doi.org/10.1038/s41467-018-07905-4
51	A Sehrawat, L Gao, Y Wang, A 3rd Bankhead, SK McWeeney, CJ King, J Schwartzman, J Urrutia, WH Bisson, DJ Colemanet al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci USA 115:E4179–E4188 https://doi.org/10.1158/1538-7445.AM2018-LB-240
52	T Sekiya, UM Muthurajan, K Luger, AV Tulin, KS Zaret (2009) Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. Genes Dev 23:804–809 https://doi.org/10.1101/gad.1775509
53	AA Sérandour, S Avner, F Percevault, F Demay, M Bizot, C Lucchetti-Miganeh, F Barloy-Hubler, M Brown, M Lupien, R Métivieret al. (2011) Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res 21:555–565 https://doi.org/10.1101/gr.111534.110
54	Y Shi, F Lan, C Matson, P Mulligan, JR Whetstine, PA Cole, RA Casero, Y Shi (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941–953 https://doi.org/10.1016/j.cell.2004.12.012
55	B Song, S-H Park, JC Zhao, K-W Fong, S Li, Y Lee, YA Yang, S Sridhar, X Lu, SA Abdulkadiret al. (2019) Targeting FOXA1-mediated repression of TGF-β signaling suppresses castrationresistant prostate cancer progression. J Clin Invest 129:569–582 https://doi.org/10.1172/JCI122367
56	P Sutinen, V Rahkama, M Rytinki, JJ Palvimo (2014) Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation. Mol Endocrinol 28:1719–1728 https://doi.org/10.1210/me.2014-1035
57	Q Szabo, F Bantignies, G Cavalli (2019) Principles of genome folding into topologically associating domains. Sci Adv 5: eaaw1668 https://doi.org/10.1126/sciadv.aaw1668
58	D Wang, I Garcia-Bassets, C Benner, W Li, X Su, Y Zhou, J Qiu, W Liu, MU Kaikkonen, KA Ohgiet al. (2011) Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474:390–394 https://doi.org/10.1038/nature10006
59	J Wang, S Hevi, JK Kurash, H Lei, F Gay, J Bajko, H Su, W Sun, H Chang, G Xuet al.(2009a) The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 41:125–129 https://doi.org/10.1038/ng.268
60	Q Wang, W Li, Y Zhang, X Yuan, K Xu, J Yu, Z Chen, R Beroukhim, H Wang, M Lupienet al. (2009b) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245–256 https://doi.org/10.1016/j.cell.2009.04.056
61	S Wang, S Singh, M Katika, S Lopez-Aviles, A Hurtado (2018) High throughput chemical screening reveals multiple regulatory proteins on FOXA1 in breast cancer cell lines. International Journal of Molecular Sciences 19:4123 https://doi.org/10.3390/ijms19124123
62	PA Watson, VK Arora, CL Sawyers (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15:701–711 https://doi.org/10.1038/nrc4016
63	T Whitington, P Gao, W Song, H Ross-Adams, AD Lamb, Y Yang, I Svezia, D Klevebring, IG Mills, R Karlssonet al. (2016) Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nat Genet 48:387–397 https://doi.org/10.1038/ng.3523
64	M Wissmann, N Yin, JM Müller, H Greschik, BD Fodor, T Jenuwein, C Vogler, R Schneider, T Günther, R Buettneret al. (2007) Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9:347–353 https://doi.org/10.1038/ncb1546
65	Q Wu, D Heidenreich, S Zhou, S Ackloo, A Krämer, K Nakka, E Lima-Fernandes, G Deblois, S Duan, RN Vellankiet al. (2019) A chemical toolbox for the study of bromodomains and epigenetic signaling. Nat Commun 10:1915 https://doi.org/10.1038/s41467-019-09672-2
66	B Xu, B Song, X Lu, J Kim, M Hu, JC Zhao, J Yu (2019) Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression. Cell Res 29:773–775 https://doi.org/10.1038/s41422-019-0204-1
67	N Yamaguchi, M Shibazaki, C Yamada, E Anzai, M Morii, Y Nakayama, T Kuga, Y Hashimoto, T Tomonaga, N Yamaguchi (2017) Tyrosine phosphorylation of the pioneer transcription factor FoxA1 promotes activation of estrogen signaling. J Cell Biochem 118:1453–1461 https://doi.org/10.1002/jcb.25804
68	X Zhang, SD Bailey, M Lupien (2014) Laying a solid foundation for Manhattan–’setting the functional basis for the post-GWAS era’. Trends Genet 30:140–149 https://doi.org/10.1016/j.tig.2014.02.006
69	X Zhang, R Cowper-Sal-lari, SD Bailey, JH Moore, M Lupien (2012) Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus. Genome Research 22:1437–1446 https://doi.org/10.1101/gr.135665.111
70	S Zhou, JR Hawley, F Soares, G Grillo, M Teng, SA Madani Tonekaboni, JT Hua, KJ Kron, P Mazrooei, M Ahmedet al. (2020) Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nat Commun 11:441 https://doi.org/10.1038/s41467-020-14318-9
71	S Zhou, AE Treloar, M Lupien (2016) Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. Cancer Discov 6:1215–1229 https://doi.org/10.1158/2159-8290.CD-16-0745

[1]	Qingfei Zheng, Igor Maksimovic, Akhil Upad, Yael David. Non-enzymatic covalent modifications: a new link between metabolism and epigenetics[J]. Protein Cell, 2020, 11(6): 401-416.
[2]	Lin-Yong Zhao, Jinghui Song, Yibin Liu, Chun-Xiao Song, Chengqi Yi. Mapping the epigenetic modifications of DNA and RNA[J]. Protein Cell, 2020, 11(11): 792-808.
[3]	Lili Yu, Kai-yuan Ji, Jian Zhang, Yanxia Xu, Yue Ying, Taoyi Mai, Shuxiang Xu, Qian-bing Zhang, Kai-tai Yao, Yang Xu. Core pluripotency factors promote glycolysis of human embryonic stem cells by activating GLUT1 enhancer[J]. Protein Cell, 2019, 10(9): 668-680.
[4]	Xiangxian Zhang, Li Liu, Xia Yuan, Yuquan Wei, Xiawei Wei. JMJD3 in the regulation of human diseases[J]. Protein Cell, 2019, 10(12): 864-882.
[5]	Chao Zhong, Jinfang Zhu. Transcriptional regulators dictate innate lymphoid cell fates[J]. Protein Cell, 2017, 8(4): 242-254.
[6]	Haley Vaseghi, Jiandong Liu, Li Qian. Molecular barriers to direct cardiac reprogramming[J]. Protein Cell, 2017, 8(10): 724-734.
[7]	Donglu Wu, Yong Cai, Jingji Jin. Potential coordination role between O-GlcNAcylation and epigenetics[J]. Protein Cell, 2017, 8(10): 713-723.
[8]	Qianqian Liang,Chen Xu,Xinyun Chen,Xiuya Li,Chao Lu,Ping Zhou,Lianhua Yin,Ruizhe Qian,Sifeng Chen,Zhendong Ling,Ning Sun. The roles of Mesp family proteins: functional diversity and redundancy in differentiation of pluripotent stem cells and mammalian mesodermal development[J]. Protein Cell, 2015, 6(8): 553-561.
[9]	Joo-Man Park,Seong-Ho Jo,Mi-Young Kim,Tae-Hyun Kim,Yong-Ho Ahn. Role of transcription factor acetylation in the regulation of metabolic homeostasis[J]. Protein Cell, 2015, 6(11): 804-813.
[10]	David M. Roy,Logan A. Walsh,Timothy A. Chan. Driver mutations of cancer epigenomes[J]. Protein Cell, 2014, 5(4): 265-296.
[11]	Rui Chen, Shancheng Ren, Yinghao Sun. Genome-wide association studies on prostate cancer: the end or the beginning?[J]. Prot Cell, 2013, 4(9): 677-686.
[12]	Yewei Liu, Qian Reuben Xie, Boshi Wang, Jiaxiang Shao, Tingting Zhang, Tengyuan Liu, Gang Huang, Weiliang Xia. Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics[J]. Prot Cell, 2013, 4(9): 702-710.
[13]	Yeqing Angela Yang, Jindan Yu. EZH2, an epigenetic driver of prostate cancer[J]. Prot Cell, 2013, 4(5): 331-341.
[14]	Jijing Luo, Xiaoqi Liu. Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development[J]. Prot Cell, 2012, 3(3): 182-197.
[15]	Jigang Li, William Terzaghi, Xing Wang Deng. Genomic basis for light control of plant development[J]. Prot Cell, 2012, 3(2): 106-116.

Viewed

Full text

Abstract

Cited

Shared

Discussed